It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...

As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...

Experts discuss the complexities of advanced imaging in cancer diagnosis, highlighting challenges with PET scans and the importance of accurate interpretation. This episode, titled ‘InterpretingPSMA ...

Central Montana Medical Center is taking a major step forward in expanding access to advanced cancer care with the arrival of a new mobile PET/CT scan unit, now available every other Thursday in ...

In amyloid PET, visual and quantitative reads are at odds 6 percent of the time. In some instances, regional accumulation might be to blame. People with discordant scans accumulated amyloid faster ...

Imagine being able to see the invisible—amyloid plaques, tau tangles, and metabolic changes in the living brain. This is no longer science fiction; it’s reality at the University of Kentucky. Dr. Greg ...

Anok Yai underwent a “difficult, life-saving procedure” after developing sepsis shortly after undergoing lung surgery, Page Six can exclusively reveal. A source tells us the 28-year-old supermodel was ...

At the San Antonio Breast Cancer Symposium, Jennifer Specht, MD, of the University of Washington and Fred Hutch Cancer Center, Seattle, presented results from the ECOG-ACRIN FEATURE trial, a phase II ...